{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T05:59:52Z","timestamp":1790488792442,"version":"4.1.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,8,29]],"date-time":"2018-08-29T00:00:00Z","timestamp":1535500800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004320","name":"Shiraz University of Medical Sciences","doi-asserted-by":"publisher","award":["IR.SUMS.REC.1395.102,"],"award-info":[{"award-number":["IR.SUMS.REC.1395.102,"]}],"id":[{"id":"10.13039\/501100004320","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s13063-018-2843-9","type":"journal-article","created":{"date-parts":[[2018,8,29]],"date-time":"2018-08-29T17:11:57Z","timestamp":1535562717000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["The effectiveness of different singly administered high doses of buprenorphine in reducing suicidal ideation in acutely depressed people with co-morbid opiate dependence: a randomized, double-blind, clinical trial"],"prefix":"10.1186","volume":"19","author":[{"given":"Jamshid","family":"Ahmadi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mina Sefidfard","family":"Jahromi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra","family":"Ehsaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,8,29]]},"reference":[{"issue":"17","key":"2843_CR1","first-page":"5","volume":"62","author":"Centers for Disease Control and Prevention","year":"2013","unstructured":"Centers for Disease Control and Prevention. Suicide Among Adults Aged 35\u201364 Years \u2014 United States, 1999\u20132010. MMWR Morb Mortal Wkly Rep. 2013;62(17):5.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"10","key":"2843_CR2","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1001\/archpsyc.62.10.1122","volume":"62","author":"M Olfson","year":"2005","unstructured":"Olfson M, et al. Emergency treatment of young people following deliberate self-harm. Arch Gen Psychiatry. 2005;62(10):1122\u20138.","journal-title":"Arch Gen Psychiatry"},{"issue":"8","key":"2843_CR3","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1017\/S1461145711000629","volume":"14","author":"GL Larkin","year":"2011","unstructured":"Larkin GL, Beautrais AL. A preliminary naturalistic study of low-dose ketamine for depression and suicide ideation in the emergency department. Int J Neuropsychopharmacol. 2011;14(8):1127\u201331.","journal-title":"Int J Neuropsychopharmacol"},{"key":"2843_CR4","doi-asserted-by":"publisher","first-page":"f3646","DOI":"10.1136\/bmj.f3646","volume":"346","author":"A Cipriani","year":"2013","unstructured":"Cipriani A, et al. Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis. BMJ. 2013;346:f3646.","journal-title":"BMJ"},{"issue":"3","key":"2843_CR5","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.brs.2014.03.006","volume":"7","author":"MS George","year":"2014","unstructured":"George MS, et al. A two-site pilot randomized 3 day trial of high dose left prefrontal repetitive transcranial magnetic stimulation (rTMS) for suicidal inpatients. Brain Stimul. 2014;7(3):421\u201331.","journal-title":"Brain Stimul"},{"issue":"1","key":"2843_CR6","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1097\/YCT.0b013e3182a6ad0d","volume":"30","author":"M Fink","year":"2014","unstructured":"Fink M, Kellner CH, McCall WV. The role of ECT in suicide prevention. J ECT. 2014;30(1):5\u20139.","journal-title":"J ECT"},{"issue":"2","key":"2843_CR7","doi-asserted-by":"publisher","first-page":"169","DOI":"10.2190\/PM.47.2.g","volume":"47","author":"JM Striebel","year":"2014","unstructured":"Striebel JM, Kalapatapu RK. The anti-suicidal potential of buprenorphine: a case report. Int J Psychiatry Med. 2014;47(2):169\u201374.","journal-title":"Int J Psychiatry Med"},{"issue":"5","key":"2843_CR8","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1176\/appi.ajp.2015.15040535","volume":"173","author":"Y Yovell","year":"2016","unstructured":"Yovell Y, et al. Ultra-low-dose buprenorphine as a time-limited treatment for severe suicidal ideation: a randomized controlled trial. Am J Psychiatry. 2016;173(5):491\u20138.","journal-title":"Am J Psychiatry"},{"issue":"1","key":"2843_CR9","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.biopsych.2006.04.043","volume":"61","author":"M Greenwald","year":"2007","unstructured":"Greenwald M, et al. Buprenorphine duration of action: mu-opioid receptor availability and pharmacokinetic and behavioral indices. Biol Psychiatry. 2007;61(1):101\u201310.","journal-title":"Biol Psychiatry"},{"issue":"194","key":"2843_CR10","first-page":"62354","volume":"67","author":"Drug Enforcement Administration, Department of Justice","year":"2002","unstructured":"Drug Enforcement Administration, Department of Justice. Schedules of controlled substances: rescheduling of buprenorphine from schedule V to schedule III. Final rule. Fed Regist. 2002;67(194):62354\u201370.","journal-title":"Fed Regist"},{"issue":"2:7","key":"2843_CR11","first-page":"3","volume":"1","author":"J Ahmadi","year":"2016","unstructured":"Ahmadi J. The effect of buprenorphine on the reduction of cannabis and heroin craving and suicidal thoughts: a new finding. iMedPub. 2016;1(2:7):3.","journal-title":"iMedPub"},{"key":"2843_CR12","doi-asserted-by":"publisher","unstructured":"Ahmadi J. Fast treatment of methamphetamine related anxiety and depressive disorders: a novel approach. J Addict Med Ther Sci. 1(2):044\u20136. https:\/\/doi.org\/10.17352\/2455-3484.000011.","DOI":"10.17352\/2455-3484.000011."},{"issue":"1","key":"2843_CR13","first-page":"3","volume":"4","author":"J Ahmadi","year":"2016","unstructured":"Ahmadi J. Instant detoxification of heroin with high dose of buprenorphine. J Addict Prev. 2016;4(1):3.","journal-title":"J Addict Prev"},{"key":"2843_CR14","unstructured":"Gracer R. The buprenorphine effect on depression. The National Alliance of Advocates for Buprenorphine Treatment (NAABT) Vol 3, No 2, Feb. 2007 newsletter."},{"key":"2843_CR15","volume-title":"Kaplan & Sadock\u2019s Synopsis of Psychiatry","year":"2015","unstructured":"Sadock B, Sadock V, Ruiz P, editors. Kaplan & Sadock\u2019s Synopsis of Psychiatry. Philadelphia: Lippincott Williams & Wilkins; 2015."},{"key":"2843_CR16","unstructured":"Ahmadi J, Sefidfard Jahromi M. Ultrarapid Influence of Buprenorphine on Major Depression in Opioid-Dependent Patients: A Double Blind, Randomized Clinical Trial. Subst Use Misuse. 2017;17:1\u20134."},{"issue":"1","key":"2843_CR17","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.psyneuen.2012.05.002","volume":"38","author":"JC Ipser","year":"2013","unstructured":"Ipser JC, Terburg D, Syal S, Phillips N, Solms M, Panksepp J, van Honk J. Reduced fear-recognition sensitivity following acute buprenorphine administration in healthy volunteers. Psychoneuroendocrinology. 2013;38(1):166\u201370.","journal-title":"Psychoneuroendocrinology"},{"issue":"1","key":"2843_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1744-859X-10-17","volume":"10","author":"AGI Maremmani","year":"2011","unstructured":"Maremmani AGI, Rovai L, Pani PP, Pacini M, Lamanna F, Rugani F, Maremmani I. Do methadone and buprenorphine have the same impact on psychopathological symptoms of heroin addicts? Ann General Psychiatry. 2011;10(1):1.","journal-title":"Ann General Psychiatry"},{"issue":"5","key":"2843_CR19","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1007\/s00213-014-3723-y","volume":"232","author":"E Falcon","year":"2015","unstructured":"Falcon E, Maier K, Robinson SA, Hill-Smith TE, Lucki I. Effects of buprenorphine on behavioral tests for antidepressant and anxiolytic drugs in mice. Psychopharmacology. 2015;232(5):907\u201315.","journal-title":"Psychopharmacology"},{"issue":"4","key":"2843_CR20","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1002\/1097-4679(198807)44:4<499::AID-JCLP2270440404>3.0.CO;2-6","volume":"44","author":"AT Beck","year":"1988","unstructured":"Beck AT, Steer RA, Ranieri WF. Scale for suicide ideation: psychometric properties of a self-report version. J Clin Psychol. 1988;44(4):499\u2013505.","journal-title":"J Clin Psychol"},{"key":"2843_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/SAR.S45585","volume":"6","author":"M Soyka","year":"2015","unstructured":"Soyka M. New developments in the management of opioid dependence: focus on sublingual buprenorphine\u2013naloxone. Subst Abuse Rehabil. 2015;6:1\u201314. https:\/\/doi.org\/10.2147\/SAR.S45585 .","journal-title":"Subst Abuse Rehabil"},{"key":"2843_CR22","first-page":"5","volume":"9","author":"MZ Mintzer","year":"2007","unstructured":"Mintzer MZ. Effects of opioid pharmacotherapy on psychomotor and cognitive performance: a review of human laboratory studies of methadone and buprenorphine. Heroin Addict Relat Clin Prob. 2007;9:5\u201324.","journal-title":"Heroin Addict Relat Clin Prob"},{"key":"2843_CR23","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/S0376-8716(97)00117-8","volume":"48","author":"S Darke","year":"1997","unstructured":"Darke S, Ross J. Polydrug dependence and psychiatric comorbidity among heroin injectors. Drug Alcohol Depend. 1997;48:135\u201341.","journal-title":"Drug Alcohol Depend"},{"key":"2843_CR24","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1080\/09595230500286039","volume":"24","author":"J Ross","year":"2005","unstructured":"Ross J, Teesson M, Darke S, et al. The characteristics of heroin users entering treatment: findings from the Australian treatment outcome study (ATOS). Drug Alcohol Rev. 2005;24:411\u20138.","journal-title":"Drug Alcohol Rev"},{"key":"2843_CR25","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1001\/archpsyc.1982.04290020021004","volume":"39","author":"BJ Rounsaville","year":"1982","unstructured":"Rounsaville BJ, Weissman MM, Crits-Christoph K, Wilber C, Kleber H. Diagnosis and symptoms of depression in opiate addicts. Course and relationship to treatment outcome. Arch Gen Psychiatry. 1982;39:151\u20136.","journal-title":"Arch Gen Psychiatry"},{"key":"2843_CR26","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.drugalcdep.2012.06.020","volume":"127","author":"JD Savant","year":"2013","unstructured":"Savant JD, Barry DT, Cutter CJ, et al. Prevalence of mood and substance use disorders among patients seeking primary care office-based buprenorphine\/naloxone treatment. Drug Alcohol Depend. 2013;127:243\u20137.","journal-title":"Drug Alcohol Depend"},{"key":"2843_CR27","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1080\/17523281.2011.533452","volume":"4","author":"I Sch\u00e4fer","year":"2011","unstructured":"Sch\u00e4fer I, Fischer M, Reimer J, Karow A, Haasen C. Significance of psychiatric comorbidity for the outcome of maintenance treatment \u2014 a review of the literature. Ment Health Subst Use. 2011;4:62\u201371.","journal-title":"Ment Health Subst Use"},{"key":"2843_CR28","doi-asserted-by":"publisher","first-page":"S14","DOI":"10.1097\/00002508-200207001-00003","volume":"18","author":"EC Strain","year":"2002","unstructured":"Strain EC. Assessment and treatment of comorbid psychiatric disorders in opioid-dependent patients. Clin J Pain. 2002;18:S14\u201327.","journal-title":"Clin J Pain"},{"key":"2843_CR29","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/S0306-4603(98)00076-8","volume":"23","author":"KR Merikangas","year":"1998","unstructured":"Merikangas KR, Mehta RL, Molnar BE, et al. Comorbidity of substance use disorders with mood and anxiety disorders: results of the International Consortium in Psychiatric Epidemiology. Addict Behav. 1998;23:893\u2013907.","journal-title":"Addict Behav"},{"key":"2843_CR30","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1001\/archpsyc.60.9.993","volume":"60","author":"KR Merikangas","year":"2003","unstructured":"Merikangas KR, Zhang H, Avenevoli S, Acharyya S, Neuenschwander M, Angst J. Longitudinal trajectories of depression and anxiety in a prospective community study: the Zurich Cohort Study. Arch Gen Psychiatry. 2003;60:993\u20131000.","journal-title":"Arch Gen Psychiatry"},{"key":"2843_CR31","first-page":"327","volume":"15","author":"F Moggi","year":"2013","unstructured":"Moggi F. Etiological models on the relationship of mental disorders and substance use disorders. Suchtmed. 2013;15:327\u201333. German","journal-title":"Suchtmed"},{"key":"2843_CR32","unstructured":"Soyka M. Affective and anxiety disorders and drug addiction. Suchtmed, German. 2013;15:341\u20138."},{"key":"2843_CR33","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.psychres.2007.12.007","volume":"166","author":"S Darke","year":"2009","unstructured":"Darke S, Mills K, Teesson M, Ross J, Williamson A, Havard A. Patterns of major depression and drug-related problems amongst heroin users across 36 months. Psychiatry Res. 2009;166:7\u201314.","journal-title":"Psychiatry Res"},{"key":"2843_CR34","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1097\/ADT.0b013e318215f322","volume":"10","author":"M Torrens","year":"2011","unstructured":"Torrens M, Mart\u00ednez-Sanvisens D, Mart\u00ednez-Riera R, Bulbena A, Szerman N, Ruiz P. Dual diagnosis: focusing on depression and recommendations for treatment of opioid dependence. Addict Disord Treat. 2011;10:50\u20139.","journal-title":"Addict Disord Treat"},{"key":"2843_CR35","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/S0740-5472(99)00074-4","volume":"18","author":"RB Rothman","year":"2000","unstructured":"Rothman RB, Gorelick DA, Heishman SJ, et al. An open-label study of a functional opioid kappa antagonist in the treatment of opioid dependence. J Subst Abus Treat. 2000;18:277\u201381.","journal-title":"J Subst Abus Treat"},{"key":"2843_CR36","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1097\/00004714-199502000-00008","volume":"15","author":"JA Bodkin","year":"1995","unstructured":"Bodkin JA, Zornberg GL, Lukas SE, Cole JO. Buprenorphine treatment of refractory depression. J Clin Psychopharmacol. 1995;15:49\u201357.","journal-title":"J Clin Psychopharmacol"},{"key":"2843_CR37","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/S0140-6736(82)90727-9","volume":"2","author":"HM Emrich","year":"1982","unstructured":"Emrich HM, Vogt P, Herz A, Kissling W. Antidepressant effects of buprenorphine. Lancet. 1982;2:709.","journal-title":"Lancet"},{"key":"2843_CR38","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.pnpbp.2005.10.007","volume":"30","author":"G Gerra","year":"2006","unstructured":"Gerra G, Leonardi C, D\u2019Amore A, et al. Buprenorphine treatment outcome in dually diagnosed heroin dependent patients: a retrospective study. Prog Neuro-Psychopharmacol Biol Psychiatry. 2006;30:265\u201372.","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"key":"2843_CR39","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1176\/ajp.144.10.1340","volume":"144","author":"C Schmauss","year":"1987","unstructured":"Schmauss C, Yassouridis A, Emrich HM. Antipsychotic effect of buprenorphine in schizophrenia. Am J Psychiatry. 1987;144:1340\u20132.","journal-title":"Am J Psychiatry"},{"key":"2843_CR40","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s00213-010-1825-8","volume":"210","author":"S Wee","year":"2010","unstructured":"Wee S, Koob GF. The role of the dynorphin-kappa opioid system in the reinforcing effects of drugs of abuse. Psychopharmacology. 2010;210:121\u201335.","journal-title":"Psychopharmacology"},{"key":"2843_CR41","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s00213-003-1680-y","volume":"172","author":"MS Todtenkopf","year":"2004","unstructured":"Todtenkopf MS, Marcus JF, Portoghese PS, Carlezon WA Jr. Effects of kappa-opioid receptor ligands on intracranial self-stimulation in rats. Psychopharmacology. 2004;172:463\u201370.","journal-title":"Psychopharmacology"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-018-2843-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13063-018-2843-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-018-2843-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T17:39:39Z","timestamp":1693849179000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-018-2843-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,29]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["2843"],"URL":"https:\/\/doi.org\/10.1186\/s13063-018-2843-9","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,29]]},"assertion":[{"value":"5 September 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"JA: Professor of Psychiatry, Founding Director of Substance Abuse Research Center. MS and ZE: Department of Psychiatry, Shiraz University of Medical Sciences.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 information"}},{"value":"Dr. Hashemi verified ethical approval (, registration date: 2017-01-24). Informed consent has been obtained from all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The patients have agreed to the publication of data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"462"}}